Suvretta Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Suvretta Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$811K	Hold	10,800	–	–	0.02%	80
2025 Q4	$854K	Hold	10,800	–	–	0.02%	84
2025 Q3	$707K	Hold	10,800	–	–	0.02%	86
2025 Q2	$427K	Hold	10,800	–	–	0.01%	91
2025 Q1	$326K	Hold	10,800	–	–	0.01%	98
2024 Q4	$378K	Hold	10,800	–	–	0.01%	91
2024 Q3	$433K	Hold	10,800	–	–	0.01%	93
2024 Q2	$515K	Hold	10,800	–	–	0.02%	89
2024 Q1	$468K	Buy	+10,800	New	+$515K	0.02%	96

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Suvretta Capital Management's IONS Position: Q1 2026 in Review

Suvretta Capital Management held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 10,800 shares worth $811K. The position accounts for 0.02% of the portfolio, ranked #80.

Suvretta Capital Management first reported a position in IONS in Q1 2024 and has held it in 9 quarters since. The position peaked at $854K in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Suvretta Capital Management held 10,800 shares of Ionis Pharmaceuticals worth $811K as of Q1 2026.
Suvretta Capital Management left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
Ionis Pharmaceuticals made up 0.02% of Suvretta Capital Management's portfolio in Q1 2026, its #80 holding.
Suvretta Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Suvretta Capital Management's Ionis Pharmaceuticals position peaked at $854K in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.